title: [Medical treatment in peripheral arterial disease: a professional practice study in 262 patients].
abstract: OBJECTIVE
  Antiplatelet agents (APA), statins and angiotensin converting enzyme inhibitors (ACEI) are effective to reduce the risk of cardio-vascular events in patients with peripheral arterial disease (PAD). Few data are available on the actual prescription of these drugs in outpatients and on the effect of hospital care on the level of prescription.
  
  
  METHODS
  Retrospective study of patients hospitalized with a confirmed diagnosis of PAD over a one-year period. Comparison of medical treatments on admission and on discharge.
  
  
  RESULTS
  262 patients were included. Mean age was 73 +/- 11 years, and 29% of the patients were women. APA were present in 64% on admission and in 83% when discharged (P < 0.0001). A statin was present in 29% on admission and in 38% when discharged (P = 0.001). ACEI were present in 27% on admission and in 32% when discharged (P= 0.02). A vasodilator was present in 47% on admission and 52% when discharged (P = 0.1). 35% of the patients had isolated PAD. Compared to the patients with associated clinical coronary or cerebro-vascular disease, they were less frequently discharged on statins (respectively 26 and 45%, p = 0.003) and on ACEI (respectively 23 et 38%, P = 0.016) whereas APA were equally prescribed (respectively 82 and 84%, P= 0.7).
  
  
  CONCLUSIONS
  APA were prescribed to a majority of outpatients and the level of prescription was further improved when patients were discharged from the hospital. Statins and ACEI were insufficiently prescribed. On the other hand, vasodilator therapy remained still largely prescribed, despite the lack of any strong effect on morbidity and survival.
authors.affiliation: Département de médecine interne, centre hospitalier de Béziers, 2, rue Valentin-Hauÿ, BP 740, 34525 Béziers cedex, France.
authors.forename: C
authors.initials: C
authors.lastname: Dumas
authors.forename: S
authors.initials: S
authors.lastname: Sedighian
authors.forename: P
authors.initials: P
authors.lastname: Nangou
authors.forename: Y
authors.initials: Y
authors.lastname: Boukriche
authors.forename: B
authors.initials: B
authors.lastname: Simorre
authors.forename: E
authors.initials: E
authors.lastname: Oziol
authors.forename: J-L
authors.initials: JL
authors.lastname: Reny
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D016491:Peripheral Vascular Diseases / Q000150:complications / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010818:Practice Patterns, Physicians'; D017035:Pravastatin; D012189:Retrospective Studies; D020521:Stroke / Q000188:drug therapy
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D017035:Pravastatin